Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnett, A. H
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Metabolic Syndrome
*Obesity
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

The importance of treating cardiometabolic risk factors in patients with type 2 diabetes

Anthony H Barnett

Undergraduate Centre, Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, B9 5SS, UK.

Cardiometabolic risk factors are the combined vascular and metabolic components of risk that may lead to a cardiovascular event. There are numerous such factors. Underlying the concept of cardiometabolic risk is an association with excess visceral fat, leading to the dysregulation of the adipokines, the signalling proteins derived from adipose tissue. Changes in the levels of the adipokines – tumour necrosis factor-{alpha}, cholesteryl ester transfer protein and adiponectin, for example – can lead to alterations in insulin sensitivity and high-density lipoprotein cholesterol metabolism. At present, specific cardiometabolic risk factors are commonly managed on an individual basis. We are now moving from the era of single risk factor intervention, however, to multiple risk factor intervention in people at high cardiovascular risk, with the additional possibility of using new drug classes to target the underlying cardiometabolic problems more effectively.

Key Words: abdominal obesity • adipokines • cardiometabolic risk • type 2 diabetes • visceral fat

Diabetes and Vascular Disease Research, Vol. 5, No. 1, 9-14 (2008)
DOI: 10.3132/dvdr.2008.002


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?